Publication
Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study
Risselada, A. J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A. F., Arends, J. & Mulder, H., Feb-2012, In : Pharmacogenomics journal. 12, 1, p. 62-67 6 p.Research output: Contribution to journal › Article › Academic › peer-review
APA
Author
Harvard
Standard
Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics : a replication study. / Risselada, A. J.; Vehof, J.; Bruggeman, R.; Wilffert, B.; Cohen, D.; Al Hadithy, A. F.; Arends, J.; Mulder, H.
In: Pharmacogenomics journal, Vol. 12, No. 1, 02.2012, p. 62-67.Research output: Contribution to journal › Article › Academic › peer-review
Vancouver
BibTeX
}
RIS
TY - JOUR
T1 - Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics
T2 - a replication study
AU - Risselada, A. J.
AU - Vehof, J.
AU - Bruggeman, R.
AU - Wilffert, B.
AU - Cohen, D.
AU - Al Hadithy, A. F.
AU - Arends, J.
AU - Mulder, H.
PY - 2012/2
Y1 - 2012/2
N2 - In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C > G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome. The Pharmacogenomics Journal (2012) 12, 62-67; doi:10.1038/tpj.2010.66; published online 3 August 2010
AB - In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (-759 C/T) and rs1414334:C > G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015). No association was found between the HTR2C -759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome. The Pharmacogenomics Journal (2012) 12, 62-67; doi:10.1038/tpj.2010.66; published online 3 August 2010
KW - HTR2C
KW - antipsychotics
KW - metabolic syndrome
KW - schizophrenia
KW - INDUCED WEIGHT-GAIN
KW - 5-HT2C RECEPTOR
KW - DRUG-TREATMENT
KW - SCHIZOPHRENIC-PATIENTS
KW - C/T POLYMORPHISM
KW - OLANZAPINE
KW - PREVALENCE
U2 - 10.1038/tpj.2010.66
DO - 10.1038/tpj.2010.66
M3 - Article
VL - 12
SP - 62
EP - 67
JO - Pharmacogenomics journal
JF - Pharmacogenomics journal
SN - 1470-269X
IS - 1
ER -
ID: 5492995